Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SMFR - GeneDx Holdings Corp - Class A


Close
0.3106
0.066   21.120%

Share volume: 0
Last Updated: Mon 09 Jan 2023 10:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$0.24
0.07
26.78%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
17.74%
1 Month
13.52%
3 Months
-65.09%
6 Months
-82.45%
1 Year
-92.44%
2 Year
-97.26%
Key data
Stock price
$0.31
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.22 - $4.65
52 WEEK CHANGE
-$0.93
MARKET CAP 
118.227 M
YIELD 
N/A
SHARES OUTSTANDING 
380.642 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
2.32
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,371,266
AVERAGE 30 VOLUME 
$2,419,622
Company detail
CEO:
Region: US
Website: sema4.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis™, its innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

Recent news